The week ahead will be the official flood gate opening for earnings season. We have a very large portion of the S&P 500 Index reporting fourth-quarter earnings, and we have many Dow Jones…
ThinkstockThe dread and fear that can come with a cancer diagnosis have their roots in its killer nature. It is the number two cause of death in Americans, second only to heart…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen so far this Tuesday. There is a larger concentration around biotech and emerging pharma this morning, but that is…
ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you…
U.S. equity markets opened lower this morning and remained down throughout the day. The likely reason for the downturn is lowered expectations for corporate earnings which will get off the blocks after…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall St. research firms this Tuesday. Ameriprise Financial Inc. (NYSE: AMP) cut to Neutral at Credit Suisse. AutoZone…
ThinkstockCelgene Corporation (NASDAQ: CELG) has issued some long-term guidance which appears to be at the high-end of its previous range. The move is taking shares higher, but not just higher with a…
Jon C. Ogg ThinkstockWhen biotech stocks become as big as some of the second-tier drug stocks, it represents billions of dollars worth of value when these move 5% or 10%. That is exactly what we…
ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec…
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations we have seen from Wall St. research calls this Monday. Alliant Techsystems (NYSE: ATK) raised to Outperform at FBR Capital…
The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations we have seen from Wall St. research calls this Thursday. Activision Blizzard Inc. (NASDAQ: ATVI) started as Outperform with $16…
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement…
The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date versus the August 15 settlement date. We have tracked the key short…
